Menogenix

• James Woodruff Emlen

  Chief medical officer

• Richard C Duke

Sources: reporter.nih.gov

• National Institute on Aging

  R43, Expanded Clinical Trial of Granulocyte Colony-Stimulating Factor (G-CSF) to Treat Hot Flush and Other Vasomotor Symptoms in Women with Naturally-Occurring and Surgically-Induced Menopause, R43AG066538, $300K, 2020–2022, May 27, 2020

• National Institute on Aging

  R43, Effect of Repeated Administration of G-CSF on Hot Flashes and Other Vasomotor Symptoms of Menopause, R43AG056209, $195K, 2018–2019, May 14, 2019

Sources: reporter.nih.gov

• Anti-Müllerian Hormone Trajectories Across the Menopause Transition

  Consulting or advice, Board or leadership role, Oct 27, 2026

• Associations of blood pressure with white matter hyperintensities later in life; influence of short-term menopausal hormone therapy

  Consulting or advice, Board or leadership role, Jan 1, 2025

• Cardiometabolic outcomes in Kronos Early Estrogen Prevention Study continuation: 14-year follow-up of a hormone therapy trial

  Grants or research support, Nov 21, 2023

• Duration of the menopausal transition is longer in women with young age at onset: the multiethnic Study of Women's Health Across the Nation

  Shares or equity, Feb 1, 2017

Sources: pubmed.ncbi.nlm.nih.gov